--> -0,80% in after hours
* Reports Q1 (Mar) earnings of $0.11 per share, excluding non-recurring items, $0.12 worse than the Capital IQ Consensus of $0.23; revenues rose 41.3% year/year to $182.5 mln vs the $197.72 mln Capital IQ Consensus.
* Co reaffirms guidance for FY16, sees EPS of $1.30-1.40, excluding non-recurring items, vs. $1.34 Capital IQ Consensus Estimate; reaffirms FY16 revs of $900-970 mln, may not be comparable to $935.76 mln Capital IQ Consensus Estimate.
* U.S. net sales of XTANDI, as reported by Astellas, are reaffirms to be in a range between $1.425-1.525 billion in 2016. This represents Medivation's projection of U.S. net sales at the Astellas level